Monday, May 01, 2023 1:44:25 PM
I'd prefer a chief medical officer, or CMO.
Currently, top management has no one with previous clinical experience, actually treating patients.
Clinicians form the bulls-eye of our target market. Sales will come from prescriptions, written on- or off-label. Clinicians (mainly physicians) will write these prescriptions, once murcidencel has received marketing authorization. Yet we have no one on staff at NW Bio, much less among top management, who has ever prescribed a drug.
Not Linda.
Not Les.
Not Marnix.
Not Alton.
Not JJ.
Not Navid.
Nor anyone else that I've been able to discover.
A major blind spot, if you ask me.
-- OJ
Currently, top management has no one with previous clinical experience, actually treating patients.
Clinicians form the bulls-eye of our target market. Sales will come from prescriptions, written on- or off-label. Clinicians (mainly physicians) will write these prescriptions, once murcidencel has received marketing authorization. Yet we have no one on staff at NW Bio, much less among top management, who has ever prescribed a drug.
Not Linda.
Not Les.
Not Marnix.
Not Alton.
Not JJ.
Not Navid.
Nor anyone else that I've been able to discover.
A major blind spot, if you ask me.
-- OJ
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
